방사선피부염 시장 규모, 점유율, 동향 분석 리포트 : 제품별, 유통 채널별, 지역별, 부문 예측(2025-2030년)

Radiodermatitis Market Size, Share & Trends Analysis Report By Product (Topical, Dressings), By Distribution Channel (Hospital Pharmacies, Retail Pharmacies, Online Pharmacies), By Region, And Segment Forecasts, 2025 - 2030

US $ 5,950 ￦ 8,515,000

Unprintable PDF & Excel (Single User License)

보고서 PDF 및 엑셀을 1인만 사용할 수 있는 라이선스입니다. 텍스트 등의 복사 및 붙여넣기, 인쇄는 불가능합니다.

US $ 6,950 ￦ 9,946,000

Printable PDF & Excel (5-User License)

보고서 PDF 및 엑셀을 동일 기업 내 동일 부서에서 최대 5명까지 사용할 수 있는 라이선스입니다. 텍스트 등의 복사 및 붙여넣기, 인쇄는 가능합니다.

US $ 8,950 ￦ 12,809,000

Printable PDF & Excel (Enterprise License)

보고서 구매 기업 및 그 자회사, 관계사가 사용할 수 있는 라이선스이며, PDF 및 엑셀 텍스트 등의 복사 및 붙여넣기, 인쇄가 가능합니다.

한글목차

방사선피부염 시장 성장과 동향

Grand View Research, Inc.의 최신 리포트에 따르면 세계의 방사선피부염 시장 규모는 2030년까지 5억 5,710만 달러에 달할 것으로 예측되며, 시장은 2025-2030년에 CAGR 4.0%로 성장할 것으로 예측됩니다.

세계 암 발병률 증가는 시장 성장을 가속하는 주요 요인입니다. 암 발병률이 증가함에 따라 치료 계획의 일환으로 방사선 치료를 받는 환자가 증가하고 있으며, 2024년 2월 세계보건기구(WHO)는 2024년까지 약 20%의 사람들이 암 진단을 받을 것으로 예상되며, 남성 9명 중 1명, 여성 12명 중 1명이 암에 걸릴 것으로 예상하고 있습니다. 피부염과 같은 부작용을 관리할 수 있는 효과적인 솔루션에 대한 요구가 증가하고 있습니다. 방사선 노출로 인한 피부 염증과 손상을 특징으로 하는 이 증상은 증상 완화 및 치유 촉진에 초점을 맞춘 전문적인 치료가 필요합니다. 이에 따라 제약 및 의료기기 회사들은 방사선피부염에 대한 혁신적인 치료법과 제품 개발을 최우선 과제로 삼고 있습니다.

암 치료 중 환자 관리에 대한 인식과 중요성이 높아지면서 치료 결과를 개선하는 데 중요한 역할을 하고 있습니다. 의료 프로바이더들은 방사선피부염과 같은 방사선 치료와 관련된 부작용에 대처할 필요성을 점점 더 많이 인식하고 있으며, 2024년5월Bioengineering &T ranslational Medicine의 총평은 1980년대 후반부터 약물전달, 화장품, 조직 재생에 대한 임상적 활용을 강조합니다, 화장품, 조직 재생에 대한 하이드로겔의 임상적 활용을 강조하고 있습니다. 최근 고분자 화학 및 제조 기술의 발전으로 천연, 합성 또는 복합재료로 만든 하이드로겔 제품이 FDA 및 EMA에서 100개 이상 승인되었습니다. 이 제품들은 조직 재생, 안면 교정, 상처 치료, 약물전달 등 다양한 용도로 사용되고 있으며, 주사제와 비주사제 모두 임상시험에 사용되고 있습니다.

방사선피부염 시장 보고서 하이라이트

• 국소용 제품 부문은 2024년 71.7% 시장 점유율을 차지하며, 주로 접근성, 편의성, 경구용 대체품에 대한 우위 등으로 인해 우위를 점하고 있습니다. 크림, 젤, 연고 등 환자의 필요에 따라 다양한 제형으로 출시되어 큰 성장세를 보일 것으로 예상됩니다.
• 유통 채널 측면에서는 약국 수 증가로 인해 소매 약국 부문이 2024년 39.4%의 큰 점유율을 차지할 것으로 예상됩니다. 소매 약국은 병원에서 작성된 처방전 중 상당 부분을 차지합니다.
• 유럽은 첨단화된 의료 인프라, 피부미용 치료에 대한 높은 인지도, 방사선 치료를 받는 환자가 많아 34.0% 시장 점유율로 세계 시장을 석권했습니다.
• 북미는 유망한 성장 기회를 창출하는 중요한 R&D 구상을 통해 두 번째 시장 점유율을 차지했습니다. 이 지역의 첨단 치료 제품은 방사선피부염 산업의 성장에 기여하는 중요한 요소입니다.
• 경쟁의 특징은 주요 기업이 제품 출시, 판매 제휴, 전략적 파트너십 등의 전략을 통해 시장 점유율을 크게 확대하는 것입니다.

목차

제1장 조사 방법과 범위

제2장 개요

제3장 방사선피부염 시장 변수, 동향, 범위

• 시장 계통 전망
  • 모시장 전망
  • 관련/부수 시장 전망
• 시장 역학
  • 시장 성장 촉진요인 분석
  • 시장 성장 억제요인 분석
• 방사선피부염 시장 분석 툴
  • 산업 분석 - Porter의 산업 분석
  • PESTEL 분석

제4장 방사선피부염 시장 : 제품별, 추정·동향 분석

• 세계의 방사선피부염 시장 : 제품 대시보드
• 세계의 방사선피부염 시장 : 제품 변동 분석
• 세계의 방사선피부염 시장 규모와 예측과 동향 분석, 2018-2030년
• 국소
  • 코르티코스테로이드
  • 친수성 크림
  • 항생제
  • 기타
• 드레싱
  • 하이드로겔 & 하이드로콜로이드 드레싱
  • 상해 방지 필름(No Sting Barrier Films)
  • Honey Impregnated Gauze
  • 실리콘 코팅 드레싱
  • 기타

제5장 방사선피부염 시장 : 유통 채널별, 추정·동향 분석

• 세계의 방사선피부염 시장 : 유통 채널 대시보드
• 세계의 방사선피부염 시장 : 유통 채널 변동 분석
• 세계의 방사선피부염 시장 규모와 예측과 동향 분석, 2018-2030년
• 병원 약국
• 소매 약국
• 온라인 약국

제6장 방사선피부염 시장 : 국, 제품, 유통 채널에 의한 지역별, 추정·동향 분석

• 지역 대시보드
• 시장 규모와 예측 동향 분석, 2018-2030년
• 북미
  • 미국
  • 캐나다
  • 멕시코
• 유럽
  • 영국
  • 독일
  • 프랑스
  • 이탈리아
  • 스페인
  • 노르웨이
  • 스웨덴
  • 덴마크
• 아시아태평양
  • 일본
  • 중국
  • 인도
  • 호주
  • 한국
  • 태국
• 라틴아메리카
  • 브라질
  • 아르헨티나
• 중동 및 아프리카
  • 남아프리카공화국
  • 사우디아라비아
  • 아랍에미리트
  • 쿠웨이트

제7장 경쟁 구도

• 주요 제조업체에 의한 최근 동향과 영향 분석
• 기업/경쟁 분류
• 주요 기업의 시장 점유율 분석, 2024년
• 기업 개요
  • Stratpharma AG
  • Smith &Nephew
  • Molnlycke Health Care AB
  • Derma Sciences Inc.
  • ConvaTec Inc.
  • BMG Pharma SRL
  • Acelity
  • 3M
  • Alliqua BioMedical

KSA

영문 목차

영문목차

Radiodermatitis Market Growth & Trends:

The global radiodermatitis market size is expected to reach USD 557.1 million by 2030, and market is projected to grow at a CAGR of 4.0% from 2025 to 2030, according to a new report by Grand View Research, Inc.. The rising global incidence of cancer is a key factor driving the market growth. As cancer rates increase, more patients are receiving radiation therapy as part of their treatment plans. In February 2024, the WHO reported that around 20% of individuals are expected to be diagnosed with cancer at some point in their lives, with roughly 1 in 9 men and 1 in 12 women succumbing to the illness, resulting in a growing need for effective solutions to manage side effects like radiodermatitis. This condition, marked by skin irritation and damage from radiation exposure, calls for specialized treatments focused on alleviating symptoms and promoting healing. Consequently, pharmaceutical and medical device companies prioritize developing innovative therapies and products to address the radiodermatitis industry.

The growing awareness and emphasis on patient care during cancer treatment play a significant role in improving outcomes. Healthcare providers are increasingly acknowledging the need to address side effects related to radiation therapy, such as radiodermatitis. The May 2024 review in Bioengineering & Translational Medicine highlighted the clinical use of hydrogels since the late 1980s across drug delivery, cosmetics, and tissue regeneration. Recent advancements in polymer chemistry and fabrication have resulted in over 100 FDA and EMA-approved hydrogel products derived from natural, synthetic, or combined materials. These products serve various purposes, including tissue regeneration, facial correction, wound dressing, and drug delivery, and include both injectable and non-injectable options in clinical trials.

Radiodermatitis Market Report Highlights:

• The topical products segment dominated in 2024 with a market share of 71.7%, primarily due to their easy accessibility, enhanced convenience, and advantages over oral alternatives. These products are expected to experience significant growth thanks to their diverse formulations, including creams, gels, and ointments tailored to meet patient needs.
• In terms of distribution channel, the retail pharmacies segment accounted for a substantial share of 39.4% in 2024 owing to the rising number of pharmacies. Retail pharmacies capture a large percentage of prescriptions written in the hospital.
• Europe dominated the market globally with a market share of 34.0% due to advanced healthcare infrastructure, high awareness of skin care treatments, and a large patient population undergoing radiation therapy.
• North America accounted for the second-largest market share due to significant R&D initiatives that have created promising growth opportunities. Advanced therapeutic products in the region are a key factor contributing to its growth in the radiodermatitis industry.
• The competition features key players implementing strategies like product launches, distribution agreements, and strategic partnerships, which have greatly expanded their market share.

Table of Contents

Chapter 1. Methodology and Scope

• 1.1. Market Segmentation & Scope
• 1.2. Segment Definitions
  • 1.2.1. Product
  • 1.2.2. Distribution Channel
  • 1.2.3. Estimates and forecasts timeline
• 1.3. Research Methodology
• 1.4. Information Procurement
  • 1.4.1. Purchased database
  • 1.4.2. GVR's internal database
  • 1.4.3. Secondary sources
  • 1.4.4. Primary research
• 1.5. Information or Data Analysis
  • 1.5.1. Data analysis models
• 1.6. Market Formulation & Validation
• 1.7. Model Details
  • 1.7.1. Commodity flow analysis (Model 1)
  • 1.7.2. Volume price analysis (Model 2)
• 1.8. List of Secondary Sources
• 1.9. List of Primary Sources
• 1.10. Objectives

Chapter 2. Executive Summary

• 2.1. Market Outlook
• 2.2. Segment Outlook
  • 2.2.1. Product outlook
  • 2.2.2. Distribution Channel outlook
• 2.3. Competitive Insights

Chapter 3. Radiodermatitis Market Variables, Trends & Scope

• 3.1. Market Lineage Outlook
  • 3.1.1. Parent market outlook
  • 3.1.2. Related/ancillary market outlook
• 3.2. Market Dynamics
  • 3.2.1. Market driver analysis
    • 3.2.1.1. Rising incidence of cancer
    • 3.2.1.2. Advancements in dermatological treatments
    • 3.2.1.3. Growing awareness
  • 3.2.2. Market restraint analysis
    • 3.2.2.1. High treatment costs
    • 3.2.2.2. Limited availability of specialized products
• 3.3. Radiodermatitis Market Analysis Tools
  • 3.3.1. Industry Analysis - Porter's
    • 3.3.1.1. Supplier power
    • 3.3.1.2. Buyer power
    • 3.3.1.3. Substitution threat
    • 3.3.1.4. Threat of new entrant
    • 3.3.1.5. Competitive rivalry
  • 3.3.2. PESTEL Analysis
    • 3.3.2.1. Political landscape
    • 3.3.2.2. Technological landscape
    • 3.3.2.3. Economic landscape

Chapter 4. Radiodermatitis Market: Product Estimates & Trend Analysis

• 4.1. Global Radiodermatitis Market: Product Dashboard
• 4.2. Global Radiodermatitis Market: Product Movement Analysis
• 4.3. Global Radiodermatitis Market Size & Forecasts and Trend Analysis, 2018 to 2030
• 4.4. Topical
  • 4.4.1. Topical market estimates and forecasts 2018 to 2030 (USD Billion)
  • 4.4.2. Corticosteroids
    • 4.4.2.1. Corticosteroids market estimates and forecasts 2018 to 2030 (USD Billion)
  • 4.4.3. Hydrophilic Creams
    • 4.4.3.1. Hydrophilic creams market estimates and forecasts 2018 to 2030 (USD Billion)
  • 4.4.4. Antibiotics
    • 4.4.4.1. Antibiotics market estimates and forecasts 2018 to 2030 (USD Billion)
  • 4.4.5. Others
    • 4.4.5.1. Others market estimates and forecasts 2018 to 2030 (USD Billion)
• 4.5. Dressings
  • 4.5.1. Dressings market estimates and forecasts 2018 to 2030 (USD Billion)
  • 4.5.2. Hydrogel & Hydrocolloid Dressing
    • 4.5.2.1. Hydrogel & hydrocolloid dressing market estimates and forecasts 2018 to 2030 (USD Billion)
  • 4.5.3. No Sting Barrier Films
    • 4.5.3.1. No sting barrier films market estimates and forecasts 2018 to 2030 (USD Billion)
  • 4.5.4. Honey Impregnated Gauze
    • 4.5.4.1. Honey impregnated gauze market estimates and forecasts 2018 to 2030 (USD Billion)
  • 4.5.5. Silicone Coated Dressings
    • 4.5.5.1. Silicone coated dressings market estimates and forecasts 2018 to 2030 (USD Billion)
  • 4.5.6. Others
    • 4.5.6.1. Others market estimates and forecasts 2018 to 2030 (USD Billion)

Chapter 5. Radiodermatitis Market: Distribution Channel Estimates & Trend Analysis

• 5.1. Global Radiodermatitis Market: Distribution Channel Dashboard
• 5.2. Global Radiodermatitis Market: Distribution Channel Movement Analysis
• 5.3. Global Radiodermatitis Market Size & Forecasts and Trend Analysis, 2018 to 2030
• 5.4. Hospital pharmacies
  • 5.4.1. Hospital pharmacies market estimates and forecasts 2018 to 2030 (USD Billion)
• 5.5. Retail pharmacies
  • 5.5.1. Retail pharmacies market estimates and forecasts 2018 to 2030 (USD Billion)
• 5.6. Online pharmacies
  • 5.6.1. Online pharmacies market estimates and forecasts 2018 to 2030 (USD Billion)

Chapter 6. Radiodermatitis Market: Regional Estimates & Trend Analysis by Country, Product and Distribution Channel

• 6.1. Regional Dashboard
• 6.2. Market Size & Forecasts Trend Analysis, 2018 to 2030:
• 6.3. North America
  • 6.3.1. U.S.
    • 6.3.1.1. Key country dynamics
    • 6.3.1.2. Regulatory framework/ reimbursement structure
    • 6.3.1.3. Competitive scenario
    • 6.3.1.4. U.S. market estimates and forecasts 2018 to 2030, (USD Million)
  • 6.3.2. Canada
    • 6.3.2.1. Key country dynamics
    • 6.3.2.2. Regulatory framework/ reimbursement structure
    • 6.3.2.3. Competitive scenario
    • 6.3.2.4. Canada market estimates and forecasts 2018 to 2030, (USD Million)
  • 6.3.3. Mexico
    • 6.3.3.1. Key country dynamics
    • 6.3.3.2. Regulatory framework/ reimbursement structure
    • 6.3.3.3. Competitive scenario
    • 6.3.3.4. Mexico market estimates and forecasts 2018 to 2030, (USD Million)
• 6.4. Europe
  • 6.4.1. UK
    • 6.4.1.1. Key country dynamics
    • 6.4.1.2. Regulatory framework/ reimbursement structure
    • 6.4.1.3. Competitive scenario
    • 6.4.1.4. UK market estimates and forecasts 2018 to 2030, (USD Million)
  • 6.4.2. Germany
    • 6.4.2.1. Key country dynamics
    • 6.4.2.2. Regulatory framework/ reimbursement structure
    • 6.4.2.3. Competitive scenario
    • 6.4.2.4. Germany market estimates and forecasts 2018 to 2030, (USD Million)
  • 6.4.3. France
    • 6.4.3.1. Key country dynamics
    • 6.4.3.2. Regulatory framework/ reimbursement structure
    • 6.4.3.3. Competitive scenario
    • 6.4.3.4. France market estimates and forecasts 2018 to 2030, (USD Million)
  • 6.4.4. Italy
    • 6.4.4.1. Key country dynamics
    • 6.4.4.2. Regulatory framework/ reimbursement structure
    • 6.4.4.3. Competitive scenario
    • 6.4.4.4. Italy market estimates and forecasts 2018 to 2030, (USD Million)
  • 6.4.5. Spain
    • 6.4.5.1. Key country dynamics
    • 6.4.5.2. Regulatory framework/ reimbursement structure
    • 6.4.5.3. Competitive scenario
    • 6.4.5.4. Spain market estimates and forecasts 2018 to 2030, (USD Million)
  • 6.4.6. Norway
    • 6.4.6.1. Key country dynamics
    • 6.4.6.2. Regulatory framework/ reimbursement structure
    • 6.4.6.3. Competitive scenario
    • 6.4.6.4. Norway market estimates and forecasts 2018 to 2030, (USD Million)
  • 6.4.7. Sweden
    • 6.4.7.1. Key country dynamics
    • 6.4.7.2. Regulatory framework/ reimbursement structure
    • 6.4.7.3. Competitive scenario
    • 6.4.7.4. Sweden market estimates and forecasts 2018 to 2030, (USD Million)
  • 6.4.8. Denmark
    • 6.4.8.1. Key country dynamics
    • 6.4.8.2. Regulatory framework/ reimbursement structure
    • 6.4.8.3. Competitive scenario
    • 6.4.8.4. Denmark market estimates and forecasts 2018 to 2030, (USD Million)
• 6.5. Asia Pacific
  • 6.5.1. Japan
    • 6.5.1.1. Key country dynamics
    • 6.5.1.2. Regulatory framework/ reimbursement structure
    • 6.5.1.3. Competitive scenario
    • 6.5.1.4. Japan market estimates and forecasts 2018 to 2030, (USD Million)
  • 6.5.2. China
    • 6.5.2.1. Key country dynamics
    • 6.5.2.2. Regulatory framework/ reimbursement structure
    • 6.5.2.3. Competitive scenario
    • 6.5.2.4. China market estimates and forecasts 2018 to 2030, (USD Million)
  • 6.5.3. India
    • 6.5.3.1. Key country dynamics
    • 6.5.3.2. Regulatory framework/ reimbursement structure
    • 6.5.3.3. Competitive scenario
    • 6.5.3.4. India market estimates and forecasts 2018 to 2030, (USD Million)
  • 6.5.4. Australia
    • 6.5.4.1. Key country dynamics
    • 6.5.4.2. Regulatory framework/ reimbursement structure
    • 6.5.4.3. Competitive scenario
    • 6.5.4.4. Australia market estimates and forecasts 2018 to 2030, (USD Million)
  • 6.5.5. South Korea
    • 6.5.5.1. Key country dynamics
    • 6.5.5.2. Regulatory framework/ reimbursement structure
    • 6.5.5.3. Competitive scenario
    • 6.5.5.4. South Korea market estimates and forecasts 2018 to 2030, (USD Million)
  • 6.5.6. Thailand
    • 6.5.6.1. Key country dynamics
    • 6.5.6.2. Regulatory framework/ reimbursement structure
    • 6.5.6.3. Competitive scenario
    • 6.5.6.4. Thailand market estimates and forecasts 2018 to 2030, (USD Million)
• 6.6. Latin America
  • 6.6.1. Brazil
    • 6.6.1.1. Key country dynamics
    • 6.6.1.2. Regulatory framework/ reimbursement structure
    • 6.6.1.3. Competitive scenario
    • 6.6.1.4. Brazil market estimates and forecasts 2018 to 2030, (USD Million)
  • 6.6.2. Argentina
    • 6.6.2.1. Key country dynamics
    • 6.6.2.2. Regulatory framework/ reimbursement structure
    • 6.6.2.3. Competitive scenario
    • 6.6.2.4. Argentina market estimates and forecasts 2018 to 2030, (USD Million)
• 6.7. MEA
  • 6.7.1. South Africa
    • 6.7.1.1. Key country dynamics
    • 6.7.1.2. Regulatory framework/ reimbursement structure
    • 6.7.1.3. Competitive scenario
    • 6.7.1.4. South Africa market estimates and forecasts 2018 to 2030, (USD Million)
  • 6.7.2. Saudi Arabia
    • 6.7.2.1. Key country dynamics
    • 6.7.2.2. Regulatory framework/ reimbursement structure
    • 6.7.2.3. Competitive scenario
    • 6.7.2.4. Saudi Arabia market estimates and forecasts 2018 to 2030, (USD Million)
  • 6.7.3. UAE
    • 6.7.3.1. Key country dynamics
    • 6.7.3.2. Regulatory framework/ reimbursement structure
    • 6.7.3.3. Competitive scenario
    • 6.7.3.4. UAE market estimates and forecasts 2018 to 2030, (USD Million)
  • 6.7.4. Kuwait
    • 6.7.4.1. Key country dynamics
    • 6.7.4.2. Regulatory framework/ reimbursement structure
    • 6.7.4.3. Competitive scenario
    • 6.7.4.4. Kuwait market estimates and forecasts 2018 to 2030, (USD Million)

Chapter 7. Competitive Landscape

• 7.1. Recent Developments & Impact Analysis, By Key Manufacturers
• 7.2. Company/Competition Categorization
• 7.3. Key company market share analysis, 2024
• 7.4. Company Profiles
  • 7.4.1. Stratpharma AG
    • 7.4.1.1. Company overview
    • 7.4.1.2. Financial performance
    • 7.4.1.3. Product benchmarking
    • 7.4.1.4. Strategic initiatives
  • 7.4.2. Smith & Nephew
    • 7.4.2.1. Company overview
    • 7.4.2.2. Financial performance
    • 7.4.2.3. Product benchmarking
    • 7.4.2.4. Strategic initiatives
  • 7.4.3. Molnlycke Health Care AB
    • 7.4.3.1. Company overview
    • 7.4.3.2. Financial performance
    • 7.4.3.3. Product benchmarking
    • 7.4.3.4. Strategic initiatives
  • 7.4.4. Derma Sciences Inc.
    • 7.4.4.1. Company overview
    • 7.4.4.2. Financial performance
    • 7.4.4.3. Product benchmarking
    • 7.4.4.4. Strategic initiatives
  • 7.4.5. ConvaTec Inc.
    • 7.4.5.1. Company overview
    • 7.4.5.2. Financial performance
    • 7.4.5.3. Product benchmarking
    • 7.4.5.4. Strategic initiatives
  • 7.4.6. BMG Pharma S.R.L.
    • 7.4.6.1. Company overview
    • 7.4.6.2. Financial performance
    • 7.4.6.3. Product benchmarking
    • 7.4.6.4. Strategic initiatives
  • 7.4.7. Acelity
    • 7.4.7.1. Company overview
    • 7.4.7.2. Financial performance
    • 7.4.7.3. Product benchmarking
    • 7.4.7.4. Strategic initiatives
  • 7.4.8. 3M
    • 7.4.8.1. Company overview
    • 7.4.8.2. Financial performance
    • 7.4.8.3. Product benchmarking
    • 7.4.8.4. Strategic initiatives
  • 7.4.9. Alliqua BioMedical
    • 7.4.9.1. Company overview
    • 7.4.9.2. Financial performance
    • 7.4.9.3. Product benchmarking
    • 7.4.9.4. Strategic initiatives

관련자료